Publicaciones en las que colabora con Juan José Lasarte Sagastibelza (24)

2023

  1. Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma

    Nature Medicine, Vol. 29, Núm. 3, pp. 632-645

2022

  1. Gemcitabine-mediated depletion of immunosuppressive dendritic cells enhances the efficacy of therapeutic vaccination

    Frontiers in Immunology, Vol. 13

  2. Identification of HLA class I-restricted immunogenic neoantigens in triple negative breast cancer

    Frontiers in Immunology, Vol. 13

  3. Overcoming T cell dysfunction in acidic pH to enhance adoptive T cell transfer immunotherapy

    OncoImmunology, Vol. 11, Núm. 1

2021

  1. Inhibition of adjuvant-induced TAM receptors potentiates cancer vaccine immunogenicity and therapeutic efficacy

    Cancer Letters, Vol. 499, pp. 279-289

  2. Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses

    Emerging Microbes and Infections, Vol. 10, Núm. 1, pp. 1931-1946

2020

  1. Cold‐inducible rna binding protein as a vaccination platform to enhance immunotherapeutic responses against hepatocellular carcinoma

    Cancers, Vol. 12, Núm. 11, pp. 1-18

2019

  1. Enhanced anti-tumor efficacy of checkpoint inhibitors in combination with the histone deacetylase inhibitor Belinostat in a murine hepatocellular carcinoma model

    Cancer Immunology, Immunotherapy, Vol. 68, Núm. 3, pp. 379-393

2018

  1. The Toll like receptor 4 ligand cold-inducible RNA-binding protein as vaccination platform against cancer

    OncoImmunology, Vol. 7, Núm. 4

2017

  1. Blockage of FOXP3 transcription factor dimerization and FOXP3/AML1 interaction inhibits T regulatory cell activity: sequence optimization of a peptide inhibitor

    Oncotarget, Vol. 8, Núm. 42, pp. 71709-71724

  2. IL-10 expression defines an immunosuppressive dendritic cell population induced by antitumor therapeutic vaccination

    Oncotarget, Vol. 8, Núm. 2, pp. 2659-2671

2016

  1. Vaccine-induced but not tumor-derived Interleukin-10 dictates the efficacy of Interleukin-10 blockade in therapeutic vaccination

    OncoImmunology, Vol. 5, Núm. 2

2015

  1. Clinical testing of a dendritic cell targeted therapeutic vaccine in patients with chronic hepatitis C virus infection

    Molecular Therapy - Methods and Clinical Development, Vol. 2, pp. 15006

2013

  1. Helper cell-independent antitumor activity of potent CD8+ T cell epitope peptide vaccines is dependent upon CD40L

    OncoImmunology, Vol. 2, Núm. 12, pp. 1-11

2011

  1. Adjuvant combination and antigen targeting as a strategy to induce polyfunctional and high-avidity T-cell responses against poorly immunogenic tumors

    Cancer Research, Vol. 71, Núm. 9, pp. 3214-3224

  2. Improved dendritic cell-based immunization against hepatitis C virus using peptide inhibitors of interleukin 10

    Hepatology, Vol. 53, Núm. 1, pp. 23-31

2010

  1. A peptide inhibitor of FOXP3 impairs regulatory T cell activity and improves vaccine efficacy in mice

    Journal of Immunology, Vol. 185, Núm. 9, pp. 5150-5159

2009

  1. Peptide inhibitors of transforming growth factor-β enhance the efficacy of antitumor immunotherapy

    International Journal of Cancer, Vol. 125, Núm. 11, pp. 2614-2623

2008

  1. Combined immunization with adjuvant molecules poly(I:C) and anti-CD40 plus a tumor antigen has potent prophylactic and therapeutic antitumor effects

    Cancer Immunology, Immunotherapy, Vol. 57, Núm. 1, pp. 19-29

  2. In vitro and in vivo down-regulation of regulatory T cell activity with a peptide inhibitor of TGF-β1

    Journal of Immunology, Vol. 181, Núm. 1, pp. 126-135